Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma.

BACKGROUND: This prospective study was conducted to evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation in refractory, advanced glaucoma. PATIENTS AND METHODS: One hundred eyes of 100 patients with advanced glaucoma refractory to medical treatment were consecutively treated by transscleral diode laser cyclophotocoagulation. Success was defined as a final intraocular pressure between 5 and 21 mm Hg in eyes with a visual acuity of more than hard movements, relief of pain in eyes with a visual acuity of hand movements or less including blind eyes, and reduction of carbonic anhydrase inhibitor use in all eyes. RESULTS: Ninety-three patients were followed up for 1 year after initial treatment. The overall success rate was 74.2%. Of 60 eyes with a visual acuity of more than hand movements, intraocular pressure between 5 and 21 mm Hg was achieved in 41 (68.3%) eyes. Relief of pain was achieved in 28 (84.8%) of 33 eyes. Reduction of systemic carbonic anhydrase inhibitor use was highly significant (P < 0.0001). Within 1 year, 173 laser procedures (mean, 1.9 per patient) were performed. The probability of success increased significantly (P = 0.004) with the age of the patients, from 55% for patients younger than the age of 50 years to 83% for patients older than the age of 50 years. Previous ocular surgery decreased the success probability from 95% to 68% (P = 0.02). A high success rate was achieved in inflammatory glaucoma (75%), primary open-angle glaucoma (89.5%), and neovascular glaucoma (86.7%). The results were relatively poor in traumatic glaucoma (57.1%), aphakic glaucoma (57.1%), and congenital or juvenile glaucoma (62.5%). No significant relationship between loss of visual acuity and failure of treatment (P = 0.3) could be detected. No phthisis bulbi or persistent hypotonia developed. CONCLUSIONS: Transscleral diode laser cyclophotocoagulation is an effective and safe method for the treatment of advanced, refractory glaucoma. However, repeated treatments are often necessary. Success of treatment depends on the age of patients, previous surgery, and the type of glaucoma.

[Cyclocryocoagulation in treatment of therapy refractory glaucoma: a retrospective analysis of 185 cryocoagulation procedures]. / Die Zyklokryokoagulation in der Behandlung therapierefraktärer Glaukome: Eine retrospektive Analyse von 185 Zyklokryokoagulationen.

BACKGROUND: For several years it has been discussed whether cyclocryotherapy is still an up-to-date treatment of resistant inadequately controlled glaucoma. This retrospective study investigates the clinical aspects of 185 cyclocryotherapies between 1988 and 1997. PATIENTS AND METHODS: At the University Eye Clinic of Tübingen, 114 patients received in 119 eyes (64.3%) one cyclocryotherapy, and in 66 eyes (35.7%) multiple cyclocryotherapies. The standard surgical techniques for cyclocryotherapy can be summarized as followed: probe placements per eye, 4 to 6; location of probe placement, inferior circumference (63.9%); distance of the applicator from limbus, 3 mm (50.7%); temperature of the probe tip, -70 degrees C (34.2%); and time of the treatment, 60 seconds (89.9%). RESULTS: Intraocular pressure was on average 33.8 mm Hg before treatment. In all analysed glaucoma types intraocular pressure was lowered to 10.2 mm Hg (30%). The most frequent type of glaucoma was the neovascular glaucoma (55%). One year after treatment, this type showed on average, relative to all other types of glaucoma, the highest intraocular pressure (28.1 mm Hg) and a lowering of intraocular pressure by 8.3 mm Hg (22.7%). Half a year after cyclocryotherapy, a highly significant (p < 0.002) reduction of antiglaucomatous medication was achieved in comparison to the preoperative medication. CONCLUSION: Despite the fact that cyclocryotherapy is not always effective, it is an ambulant surgical technique easy to apply, non-invasive, cost-effective and can be repeated to lower intraocular pressure in resistant chronic glaucoma. We conclude that cyclocryotherapy will remain useful until new techniques, like the diode laser cyclophototherapy (especially ultrasonic controlled), are developed as alternative therapies.

Colour vision disturbances in chronic smokers.

PURPOSE: The aim of the present study was to test the influence of smoking on colour perception. SUBJECTS AND METHODS: At the University Eye Hospital Tübingen, 76 generally healthy smokers with inconspicuous ophthalmological findings (visual acuity, refraction, intraocular pressure, morphology) were examined by the cap-sorting test, Roth 28-hue desaturated. Group 1 was comprised of smokers (n = 20; M 9, F 11; mean age 28.1+/-10.3 years) with a smoking consumption of less than one packet of cigarettes per day (8.4+/-5.3 cigarettes/day) for 9.1+/-8.3 years. Group 2 consisted of smokers (n = 32; M 22, F 10; mean age 28.6+/-9.7 years) with a smoking consumption of one or more than one packet per day (30+/-8.4 cigarettes/ day) for 9.5+/-8.3 years. Generally healthy and ophthalmologically normal non-smokers served as a control group (n = 76; M 41, F 35; mean age 30+/-9 years). RESULTS: The average error score of the control group was (median +/- mean absolute deviation) 42+/-18. Group 1 showed no difference to the control group (51+/-27; P = 0.42). On the other hand, group 2 had a significantly higher error score than the control group (102+/-45; P<0.0001). CONCLUSION: Otherwise healthy smokers with a cigarette consumption of less than 20 cigarettes per day do not show any disturbances in colour vision. Smokers who consume more than 20 cigarettes per day may suffer colour vision defects as a result.

[Bilateral neuroretinitis with zoster infection]. / Schwere beidseitige Neuroretinitis bei Zosterinfektion.

BACKGROUND: Infections with varicella zoster virus may involve the optic nerve and the retina. Different pathomechanisms have been discussed. We present a case with an autoimmune inflammatory reaction according to the clinical course. PATIENT: A 69-year-old female was referred to our clinic because of suspected bilateral anterior ischemic optic neuropathy. She complained of severe visual loss the day before admission. Her ophthalmological and general history was unremarkable apart from treatment with 5 to 7.5 mg prednisolone alternately because of rheumatoid arthritis. Best corrected visual acuity was 1/15 OD and 0.1 OS. A relative afferent pupillary defect on the right eye was present. Optic disc oedema with multiple hemorrhages of the retina extending into the peripheral funds, slightly attenuated retinal arteries and macular oedema were seen fundoscopically in both eyes. THERAPY AND CLINICAL OUTCOME: After immediate treatment with steroids (initial dose 250 mg prednisolone per day) visual acuity improved. Because of a clinically suspected and serologically proven active varicella-zoster infection an additional virostatic therapy with valaciclovir was started and steroids were lowered gradually. Within 2 months, visual acuity increased to 0.8 OD and 1.0 OS. Oedema of optic discs and macula resolved and retinal hemorrhages disappeared. CONCLUSION: A severe hemorrhagic neuro-retinitis involving the optic discs was seen in the course of a varicella-zoster infection, possibly reactivated by chronic steroid therapy of a rheumatoid arthritis. Because of the normalization of visual function an ischemic pathogenesis is unlikely. An autoimmune inflammatory reaction seems to be the predominant mechanism, supported by the good effect of steroid and valaciclovir therapy.

Effect of sucralfate and basic fibroblast growth factor on fibrovascular ingrowth into hydroxyapatite and porous polyethylene alloplastic implants using a novel rabbit model.

This study investigated the effects of sucralfate and basic fibroblast growth factor (bFGF) on fibrovascular ingrowth into porous implant materials. Seven white female New Zealand rabbits underwent bilateral abdominal incisions through which porous orbital spherical or and disc-shaped implants were inserted between their abdominal muscles. Eighty hydroxyapatite (HA) and porous polyethylene (PP) implants, each material of different pore sizes, were implanted. These implants were either uncoated or coated with suspensions of polyhydroxymethylmethacrylate (hydron); hydron and sucralfate; or hydron, sucralfate, and bFGF. Implants were harvested after 1, 3, or 6 weeks. Observers classified the extent of fibrovascular ingrowth in a blind manner using light microscopy. All discs and spheres showed fibrovascular ingrowth; at 6 weeks, almost all implants were fully vascularized. Although demonstrating different degrees of fibrovascular maturity, all 3- and 6-week discs showed complete cellular ingrowth. Overall, the most extensive and mature fibrovascularization was found in HA implants, regardless of shape, duration of implantation, or angiogenic enhancing agent used. Thus, this study indicates that fibrovascular ingrowth into porous implants is more greatly affected by implant porosity and composition than by addition of angiogenic enhancing agents. Further in vivo study, using other potential angiogenesis-promoting agents as well as implants with different pore characteristics, is warranted using this reliable and predictable animal model.

Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro.

Enhanced ingrowth of fibrovascular tissue into alloplastic orbital implants is clinically desirable. Basic fibroblast growth factor (bFGF) is an angiogenic factor that promotes proliferation of endothelial cells. Sucralfate is known to bind bFGF and render it stable by protecting it from degradation. To test the ability of bFGF to stimulate endothelial cell proliferation, porous orbital implants coated with a sustained-release and bioactively-stabilized preparation of the angiogenic peptide bFGF were studied. Hydroxyapatite (HA) and porous polyethylene (PP) implant discs (15 x 3 mm) were coated with sustained-release polymer polyhydroxyethylmethacrylate (hydron), sucralfate (a bFGF stabilizer), hydron plus or hydron/sucralfate plus bFGF. Discs were placed in tissue culture wells plated with 50,000 endothelial cells/well. After 5 days, cells were trypsinized and counted electronically using a Coulter counter. Statistical analysis was performed using unpaired Student's t-test. Implant discs coated with hydron/sucralfate/bFGF had significantly increased endothelial cell proliferation compared to discs coated with hydron alone or hydron/sucralfate (p < 0.05). There was no significant difference in the degree of enhanced proliferation between the HA and PP implants treated with hydron/sucralfate/bFGF (p > 0.05). Minimal proliferation occurred around discs treated with hydron alone or hydron/sucralfate. Coating both HA and PP orbital implants with the sustained-release form of sucralfate/bFGF promoted endothelial cell proliferation in vitro. The enhanced proliferation with hydron/sucralfate/bFGF warrants further exploration in an in vivo model.

[An analysis of 148 outpatient treated occupational accidents]. / Eine Analyse von 148 ambulant behandelten, berufsgenossenschaftlichen Unfällen.

BACKGROUND: The most common eye injuries are non-perforating. Eye injuries in the workplace are a major cause of socioeconomical damage, morbidity and disability, despite well publicised standards for industrial eye protection. This study investigates the epidemiological and clinical aspects of 148 occupational cases. PATIENTS: At the University Eye Clinic of Tübingen, 709 non-perforating eye injuries were registered as occupational accidents between 1995 and 1996. Of these cases, 148 were analysed retrospectively per random. RESULTS: The 5 most common injuries of 148 patients (m/f = 138/10; mean age 33.4 +/- 12 years) were related to corneal foreign body injuries (35%), chemical burns (15.5%), sub-conjunctival foreign bodies (12%), thermal/ultraviolet injuries (11%) and contusions (7.4%). Of these patients, 22.3% were employed as construction workers and 16.2% as metal workers. At the time of examination the visual acuity of the traumatic eye was 0.9 +/- 0.3. The interval between the beginning of work and accident was 6.2 +/- 6.4 hours in average (0.5-13.5 h). Of all accidents, 8.5% were caused during the first hour of work; in contrast 45.5% of all accidents were caused after 6 hours of work. Another 12.4 +/- 14.5 hours (5min.-72 h; median 7 h) passed by until the patients arrived for eye examination at the Eye Clinic of Tübingen. Only 6% of all patients arrived within the first hour, and 29.7% after 12 hours. Of all cases, 30.4% received first-aid treatment in their company by the factory doctor or by the eye doctor before examination at the Eye Clinic. Only 6.8% of all patients had protective spectacles during work. Incapacity was seen in 30.4%; the average in total was 5.5 +/- 10 days. CONCLUSION: Despite the late examination at the Eye Clinic the functional loss was mostly little except after chemical burns. Nevertheless, most occupational accidents can be avoided with better protective devices in order to reduce the incidence of injuries and socioeconomical damage. Therefore an intense campaign about protective devices at the place of employment should be required. We conclude that education about safety glasses in the workplace by tradespeople and trades assistants during tasks for which goggles are recommended could considerably reduce the rate of occupational eye traumata. The data of the University Eye Clinic of Tübingen are useful to identify strategies to prevent eye injuries such as wider and better use of safety glasses and improvement in engineering controls.

[The effect of angiotensin-converting enzyme inhibitors on proteinuria in chronic glomerulonephritis]. / Einfluss von Angiotensin-Converting-Enzym-Hemmern auf die Proteinurie bei chronischer Glomerulonephritis.

The effect of two angiotensin-converting enzyme (ACE) inhibitors, lisinopril and captopril, on proteinuria and renal haemodynamics was investigated in 11 hypertensives (9 men, 2 women; mean age 46 +/- 16 years) with proteinuria (> 1.5 g/24 h) due to chronic glomerulonephritis and impaired renal function (glomerular filtration rate < 75 ml/min). In a randomized and double-blind cross-over trial the patients received, each time for six weeks, either lisinopril (5 mg/d, sometimes increased to 10 mg/d after 3 weeks) or captopril (twice daily 12.5 mg, sometimes increased to twice 25 mg after 3 weeks). Initially and between the individual treatment phases they were on a placebo phase for 4 weeks. The following were measured: protein excretion, including fractional clearance of albumin and IgG, plasma-renin activity and renal haemodynamics. Protein excretion was not significantly reduced by either drug (placebo: 7.1 +/- 4.0 g/d; lisinopril: 5.1 +/- 2.8 g/d; captopril: 5.4 +/- 3.0 g/d). Albumin excretion and fractional albumin clearance were significantly decreased only by lisinopril (P < 0.05), not by captopril. Plasma-renin activity was increased more by lisinopril than captopril (Placebo: 1.0 +/- 0.9 ng/ml.h; lisinopril: 5.2 +/- 2.8 ng/ml.h [P < 0.05]; captopril: 1.8 +/- 1.3 ng/ml.h [P < 0.05]). The renal haemodynamics was only slightly influenced by either drug, but captopril significantly decreased the filtration fraction in the presence of chronic glomerulonephritis and renal failure. - Resulting from their influence on the renin-angiotensin-aldosterone system, ACE inhibitors have, in addition to their known action on renal haemodynamics, an independent effect on the loading barrier of the basal membrane of the kidney.